record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
accepted
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding type[object Object] · [object Object] · [object Object] · [object Object] · [object Object] · [object Object]
evidence
source-boundexperimental · manual state transition; placebo-controlled clinical trial where source reports control arm · Homo sapiens
proof impact
packet context2 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition; placebo-controlled clinical trial where source reports control arm
evidence type
experimental
species
Homo sapiens
evidence spans
Donanemab in TRAILBLAZER-ALZ 4 demonstrates that early tau burden (low/medium tau PET) selects for greater clinical benefit; donanemab-treated participants with low/medium tau showed 35% slower iADRS decline vs. placebo at 18 months, underscoring importance of biomarker-based patient selection.
. . doi:10.1056/NEJMoa2301247 · curator_source · 10.1056/NEJMoa2301247
conditions
Provenance
source title
. . doi:10.1056/NEJMoa2301247
doi
10.1056/NEJMoa2301247
authors
reviewer:will-blair-bot
Donanemab in TRAILBLAZER-ALZ 4 demonstrates that early tau burden (low/medium tau PET) selects for greater clinical benefit; donanemab-treated participants with low/medium tau showed 35% slower iADRS decline vs. placebo at 18 months, underscoring importance of biomarker-based patient selection.
vs_5fdb514dc142a638 · source:. . doi:10.1056/NEJMoa2301247|section:curator_source · manual_curation
outgoing
No outgoing links.
incoming
No incoming links.
events
vev_c024b0951a1e22f7finding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_f7d85b7113600040finding.reviewedTRAILBLAZER-ALZ 4 head-to-head vs aducanumab demonstrated donanemab superiority on amyloid clearance at 6 months. Agent-drafted accept; eligible for human re-review.
agent:vela-curation-bot-2026-05-09 · 2026-05-09
reviewable changes
vpr_6a09c517baec09d7finding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
vpr_b6c12523a67fe3e6finding.reviewTRAILBLAZER-ALZ 4 head-to-head vs aducanumab demonstrated donanemab superiority on amyloid clearance at 6 months. Agent-drafted accept; eligible for human re-review.
applied · agent:vela-curation-bot-2026-05-09 · 2026-05-09
evaluations
No evaluation record targets this finding id.